Our funded research enterprise is growing. We have cutting edge programs in: telomerase in aging oncogenesis and proteomics.
We house one of the largest and most sophisticated university-based molecular diagnostics laboratories in the country. Our physicians and scientists are leaders in setting national and international practice standards. Because of this vitality and commitment to the highest standards of excellence, we continue to attract the best and brightest people to our programs.
VCUHS has invested over ten million dollars in our department to support our Functional Genomics Program and Molecular Diagnostics laboratory. Our research programs were strengthened with significant capital equipment acquisitions, including a MALDI mass spectrometer for analysis of proteins, the Affymetrix gene chip instrument, a tissue arrayer, a capillary electrophoresis instrument, and an automated sample preparation instrument.
Our research programs include:
Molecular Diagnostics Laboratory
Clinical Chemistry Laboratory
Transfusion Medicine Research
The faculty members in Transfusion Medicine are engaged in several major research projects. The “Age of Blood in Children in Pediatric Intensive Care Units (ABC-PICU)” study is a large, multi-center, randomized, double-blinded control trial aimed at determining if red blood cells stored for seven or fewer days will result in improved clinical outcomes in critically ill children when compared blood issued according to standard practices, which may include blood older than seven days. In another multi-center study, we are participating in an Investigational New Drug Application (IND) for “Pre-Hospital Use of Plasma for Traumatic Hemorrhage (PUPTH)”. This study involves the administration of thawed type A plasma in the pre-hospital setting for victims of poly trauma with major hemorrhage with the objectives of demonstrating that thawed plasma can be administered safely in this setting, and that such administration can improve outcomes. In addition, the apheresis unit contributed data to the NHLBI ReSTART trial, looking at the role of rituximab in the treatment of TTP. The faculty and staff in Transfusion Medicine are also involved in developing new clinical applications for cutting edge technology such as the use of DNA-based testing (genotyping) of red blood cell antigen genes to deduce detailed antigen profiles for patients that present difficult transfusion problems, such as patients who have received multiple or recent transfusions.